Article Summary

The article warns that a UK-US pharmaceutical trade deal could lead to 229,000 excess deaths because it may force the NHS to divert billions of pounds toward expensive new medicines without an overall budget increase, cutting funding for other vital services. It relies on a BMJ study and expert quotes to argue the deal benefits drug companies more than patients, while raising concerns about lack of parliamentary scrutiny. Although it presents a strong case using credible sources, it doesn’t explore potential health benefits from earlier access to new treatments or verify the study’s underlying assumptions.